Compare PII & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PII | IRON |
|---|---|---|
| Founded | 1954 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 1994 | 2020 |
| Metric | PII | IRON |
|---|---|---|
| Price | $61.38 | $76.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $62.27 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 715.1K | 367.8K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,152,000,000.00 | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | $4.51 | $283.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.14 | $40.00 |
| 52 Week High | $77.98 | $99.50 |
| Indicator | PII | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 45.22 |
| Support Level | $58.81 | $70.73 |
| Resistance Level | $71.10 | $82.89 |
| Average True Range (ATR) | 2.18 | 2.68 |
| MACD | -0.27 | -0.49 |
| Stochastic Oscillator | 25.53 | 34.56 |
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational, utility, military, and commercial purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.